Company Overview and News

633
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY

53
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?

2018-06-07 zacks
A month has gone by since the last earnings report for Corcept Therapeutics Incorporated (CORT - Free Report) . Shares have added about 6.6% in that time frame.
CORT ENL CRAI ENDP

53
CRA International (CRAI) Down 3.5% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for CRA International,Inc. (CRAI - Free Report) . Shares have lost about 3.5% in that time frame.
CORT ENL CRAI ENDP

58
Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?

2018-06-07 zacks
It has been about a month since the last earnings report for Endo International plc (ENDP - Free Report) . Shares have added about 12.4% in that time frame.
CORT ENL BDSI CRAI ENDP

53
Why Is Epizyme (EPZM) Up 16.2% Since Its Last Earnings Report?

2018-06-07 zacks
It has been about a month since the last earnings report for Epizyme, Inc. (EPZM - Free Report) . Shares have added about 16.2% in that time frame.
CORT EPZM ENL CRAI ENDP

60
Why Is Electronic Arts (EA) Up 10.6% Since Its Last Earnings Report?

2018-06-07 zacks
It has been about a month since the last earnings report for Electronic Arts Inc. (EA - Free Report) . Shares have added about 10.6% in that time frame.
EA CORT ENL CRAI ENDP

34
CORT / Corcept Therapeutics, Inc. 8-K (Current Report)

2018-06-04 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CORT

85
Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting

2018-06-04 globenewswire
MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced that it is presenting preliminary data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) to treat patients with solid tumors.
CELGZ CORT CELG

30
Update: Corcept Therapeutics Remains A Strong Buy

2018-06-01 seekingalpha
My sentiment remains the same for Corcept (CORT) since my previous article: Strong Buy. Corcept has since gained 22%, but new investors should not worry that they've missed the boat. Below I discuss several exciting updates provided by Corcept in the three months since my initial article.
CORT

670
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.
SGEN NKTR ATRS BLCM VRTX NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE RDUS BMY CALD MOR EXEL GILD BLUE XNCR SLDB NBIX CRSP GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY

699
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

2018-05-22 seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.
SGEN SCD NKTR ATRS NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN FCSC CELG GSK BLUE RDUS BMY EXEL BLUE XNCR SM NBIX GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY

33
Reader Inquiry: What's In Store For Corcept Therapeutics?

2018-05-21 seekingalpha
The stock is also a holding in the 20 stock Core Biotech (multi-year time frame) model account.
SBBP CORT

29
Corcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual Congress

2018-05-16 globenewswire
MENLO PARK, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced poster presentations at the 27th Annual Congress of the American Association of Clinical Endocrinologists (AACE) in Boston, Massachusetts (May 16 – 20).
CORT

30
CORT / Corcept Therapeutics, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
cort-10q_20180331.htm
CORT

29
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. [Operator Instructions] At this time I would like to turn the conference over to Charlie Robb. Please go ahead, sir.
CORT

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to CORT / Corcept Therapeutics, Inc. on message board site Silicon Investor.

Cortex (Cor) [formerly CORX] Earthworks Cortina
Corcept Therapeutics Incorporated (CORT) CRTQ: Cortech, Inc.
Cortelco Systems Inc-(CORT) Cortec (CRTQ)
CUSIP: 218352102